(Hypertension. 2000;35:1025.)
© 2000 American Heart Association, Inc.
Scientific Contributions |
Hypokalemia Associated With Diuretic Use and Cardiovascular Events in the Systolic Hypertension in the Elderly Program
From the Institute for Research in Extramural Medicine, Vrije Universiteit (L.V.F.), Amsterdam, The Netherlands; Sticht Center on Aging, Department of Internal Medicine, Wake Forest University Baptist Medical Center (M.P.), Winston Salem, NC; Department of Gerontology and Geriatrics, University of Florence and ‘Careggi’ Hospital (M.D.B.), Florence, Italy; Department of Preventive Medicine, University of Tennessee (G.W.S., W.C.C.), Memphis, Tenn; Veterans Affairs Medical Center (W.C.C.), Memphis, Tenn; and the Department of Internal Medicine, Wake Forest University School of Medicine (W.B.A.), Winston Salem, NC.
Correspondence to Marco Pahor, MD, Sticht Center on Aging, Department of Internal Medicine, Wake Forest University Baptist Medical Center, Medical Center Blvd, Winston Salem, NC 27157. E-mail mpahor{at}wfubmc.edu
 |
Abstract |
|---|
 Top Abstract IntroductionMethodsResultsDiscussionReferences |
|---|
Abstract—The treatment of hypertension with high-dose thiazide diuretics results in potassium depletion and a limited benefit for preventing coronary events. The clinical relevance of hypokalemia associated with low-dose diuretics has not been assessed. To determine whether hypokalemia that occurs with low-dose diuretics is associated with a reduced benefit on cardiovascular events, we analyzed data of 4126 participants in the Systolic Hypertension in the Elderly Program (SHEP), a 5-year randomized, placebo-controlled clinical trial of chlorthalidone-based treatment of isolated systolic hypertension in older persons. After 1 year of treatment, 7.2% of the participants randomized to active treatment had a serum potassium <3.5 mmol/L compared with 1% of the participants randomized to placebo (P<0.001). During the 4 years after the first annual visit, 451 participants experienced a cardiovascular event, 215 experienced a coronary event, 177 experienced stroke, and 323 died. After adjustment for known risk factors and study drug dose, the participants who received active treatment and who experienced hypokalemia had a similar risk of cardiovascular events, coronary events, and stroke as those randomized to placebo. Within the active treatment group, the risk of these events was 51%, 55%, and 72% lower, respectively, among those who had normal serum potassium levels compared with those who experienced hypokalemia (P<0.05). The participants who had hypokalemia after 1 year of treatment with a low-dose diuretic did not experience the reduction in cardiovascular events achieved among those who did not have hypokalemia.
Key Words: hypokalemia • diuretics • myocardial infarction • stroke • clinical trials
|
Introduction |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Thiazide diuretics tend to deplete potassium in a dose-dependent fashion. It has been suggested that this adverse effect may increase the risk of sudden cardiac death and limit the benefit of high-dose diuretic treatment on coronary events. In the Puget Sound Group Health Cooperative case-control study, the use of high-dose thiazide diuretics (100 mg daily) was associated with an increased risk (odds ratio=3.6) of primary cardiac arrest compared with the use of low-dose thiazide diuretics (25 mg daily).1 In the Multiple Risk Factor Intervention Trial, in the subgroup with abnormal resting ECG at baseline, the use of high-dose diuretics (50 to 100 mg per daily) was associated with a 2.4 times increased risk of sudden cardiac death compared with "usual care."2 More recent trials that used low-dose diuretics found a greater reduction in coronary events than those using high doses.3 4 5 In a meta-analysis of 18 randomized, placebo-controlled trials, high-dose diuretic therapy did not prevent coronary heart disease, whereas low-dose diuretic therapy was associated with a 28% reduction in coronary heart disease.6
The effects of low-dose diuretics on potassium depletion are considered mild, but, to the best of our knowledge, the clinical relevance of hypokalemia associated with low-dose diuretics has not been assessed. In the Systolic Hypertension in the Elderly Program (SHEP), participants randomized to low-dose chlorthalidone-based treatment had significantly lower serum potassium levels during follow-up and were more likely to have hypokalemia than those receiving placebo.3 7 The aim of this secondary analysis in SHEP was to determine whether hypokalemia associated with randomly assigned diuretic treatment affects the cardiovascular benefit of antihypertensive treatment.
|
Methods |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Design and Participants
The SHEP was a randomized, double-blind, placebo-controlled clinical trial on the efficacy of diuretic-based antihypertensive drug treatment of isolated systolic hypertension in persons
60 years of age. Isolated systolic
hypertension was defined as a systolic blood pressure of 160 to
219 mm Hg, with diastolic blood pressure <90
mm Hg. The follow-up was 5 years. The criteria for enrollment,
adjudication of end points, and primary findings of SHEP were reported
in detail elsewhere.3 The participants gave informed
consent, and the study was approved by the institutional review boards
of the study sites. For this study, 4126 patients who had a valid measurement of serum potassium at the clinic visit 1 year after randomization were included in the analyses. A total of 610 patients (of whom 58 died) who had been randomized into the SHEP but for whom serum potassium was not available at the first annual clinic visit were excluded from the analyses. The 610 patients who were excluded were older (72.8 years); had a higher baseline systolic blood pressure (171 mm Hg); had a higher serum creatinine (93.7 µmol/L); were more likely to be randomized to placebo treatment (55.5%); and were more likely to be black (20.3%), to be a current smoker (16.4%), and to have a history of diabetes (12.3%) compared with those who had a valid serum potassium measurement.
This article reports primarily on the first occurring major cardiovascular event, which included stroke, transient ischemic attack, myocardial infarction, heart failure, coronary artery bypass surgery, angioplasty, aneurysm, endarterectomy, and sudden death or rapid cardiac death (within 1 to 24 hours of the onset of severe cardiac symptoms unrelated to other known cause). In addition, fatal and nonfatal coronary heart disease (which included myocardial infarction, coronary procedures, and cardiac death), fatal and nonfatal stroke, and all-cause mortality were analyzed separately.
Intervention
The participants were randomized to active treatment or placebo.
A stepped-care treatment approach was used. The treatment goal was
systolic blood pressure <160 mm Hg or a 20 mm Hg
reduction in systolic blood pressure. In the active treatment
group, the first step was chlorthalidone 12.5 mg/d. The dosage was
doubled if the goal blood pressure was not achieved. If the goal was
not reached at the first step, atenolol 25 mg/d was added (second
step). If atenolol was not tolerated, reserpine 0.05 mg/d was
substituted. The dosage of the second step drugs could be doubled if
the goal blood pressure was not reached. Potassium supplements were
given to all participants who had serum potassium concentrations
<3.5 mmol/L at 2 consecutive visits. No active antihypertensive
agent was given to the participants randomized to placebo.
Data Analysis
During follow-up, differences in potassium decrease between the
active and placebo group and among participants with different doses of
chlorthalidone were tested with ANOVA.8 A dose trend was
tested by the polynomial linear contrasts ANOVA. Baseline and year 1
characteristics of the participants according to treatment group and
hypokalemia after 1 year were compared by means of the
2 test and ANOVA test as
appropriate.8
Cox proportional hazards regression models were used to estimate the
hazard ratio and 95% CI for the effect of hypokalemia (<3.5
mmol/L) after 1 year of active treatment on the outcomes of
interest.9 Only events occurring after the first year were
considered in the analyses of the effect of hypokalemia
observed after 1-year treatment. The 1-year change was chosen because
serum potassium decreased the most in the first year and did not
decrease significantly in the active treatment group thereafter (Figure 1). The assumption of proportionality of
hazards was assessed with log-log plots and by testing the interaction
of exposure with time.8 To assess independent associations
of hypokalemia at year 1 and subsequent outcomes, potential confounding
factors were entered into a summary model if they changed the ß of
hypokalemia by 10% in a bivariate Cox regression model. The same
adjustments were used in all models that analyzed the 4
outcomes. A variable that changed the ß by 10% for any 1 of the
4 outcomes was included in all multivariate models.
|
|
Results |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
At baseline, the average serum potassium was 4.52 mmol/L (±0.46) for both active treatment and placebo groups; 6 participants in the active treatment group and 9 in the placebo group had hypokalemia (serum potassium <3.5 mmol/L) (P=0.30). During follow-up, and especially in the first year, potassium levels decreased significantly more in the active treatment group compared with the placebo group (Figure 1). After 1 year, the average serum potassium was 4.09 mmol/L (±0.48) in the active treatment group and 4.45 mmol/L (±0.43) in the placebo group (P<0.001); 151 (7.2%) participants in the diuretic group had hypokalemia compared with 21 (1.0%) in the placebo group (P<0.001).
Chlorthalidone dose prescribed at the last clinic visit before the first annual visit was inversely associated with serum potassium levels at the first annual visit (P for trend <0.001) (Figure 2). The use of 6.25, 12.5, or 25.0 mg of chlorthalidone per day was associated with a significantly lower serum potassium level than the use of placebo.
|
Baseline characteristics according to treatment group and hypokalemia after 1 year are shown in Table 1. In the active treatment group, participants who experienced hypokalemia after 1 year were at baseline younger; had a slightly higher diastolic blood pressure; were more likely to be treated with antihypertensive medication at initial contact; had lower serum potassium, serum creatinine, and serum glucose levels; and were less likely to report a history of diabetes compared with those who did not experience hypokalemia. In the placebo group, virtually the same differences in characteristics were observed between those who were hypokalemic after 1 year and those who were not, but because of the small numbers, the difference did not always reach statistical significance. Furthermore, participants in the placebo group who experienced hypokalemia after 1 year also had a higher systolic blood pressure and were more likely to smoke at baseline.
|
At year 1, participants in the active treatment group who experienced hypokalemia had higher levels of serum triglycerides and serum uric acid compared with those who did not experience hypokalemia (Table 2). Both active treatment subgroups had the same proportion of participants on open-label antihypertensive medications, but those who were hypokalemic were more likely to use a higher dose of chlorthalidone (prescribed at the last clinic visit before the first annual clinic visit). In the placebo group at year 1, the participants who were hypokalemic had a lower systolic blood pressure, a higher serum uric acid level, and a greater proportion of them used open-label antihypertensive medications compared with those who were not hypokalemic.
|
During the 4 years after the first annual visit, 451 participants
experienced any cardiovascular event, 215 experienced
coronary heart disease, 177 experienced stroke, and 323 died
(Table 3). Participants in the placebo
group who had no hypokalemia, experienced more
cardiovascular events (P<0.001) and strokes
(P<0.001) than the corresponding participants in the active
treatment group. In the active treatment group, unadjusted rates of
cardiovascular events, coronary heart disease,
and stroke were significantly higher (P<0.05) among those
who were hypokalemic after 1 year compared with those who were not.
Sudden cardiac death occurred in 18 participants of the active,
nonhypokalemic subgroup; in 2 participants of the active, hypokalemic
subgroup; and in 9 participants of the placebo, nonhypokalemic subgroup
(P=0.29). After adjustment for age; gender; race; body mass
index; alcohol use; smoking; history of heart attack, stroke, and
diabetes; baseline potassium; year 1 serum creatinine,
serum glucose, serum cholesterol, serum
triglycerides, serum HDL-cholesterol, serum
uric acid; and study drug dose, the hazard ratios HR of stroke and any
cardiovascular event were significantly lower for
normokalemic (K3.5 mmol/L) participants in the active treatment
group compared with normokalemic participants in the placebo group
(Table 4). But, participants in the
active treatment group who were hypokalemic after 1 year experienced a
similar risk of coronary heart disease, stroke, and any
cardiovascular event as those in the placebo group. No
significant difference was found in the relative risk of all-cause
mortality. A direct comparison within the active treatment group showed
that those who did not experience hypokalemia after 1 year had a
significantly lower risk of coronary heart disease, stroke, and
any cardiovascular event compared with those who were
hypokalemic (Table 4). The findings were virtually unchanged
after stratification on chlorthalidone dose or when the
analyses were restricted to the participants who had a
compliance with study drugs 80% as determined by pill count (data
not shown). There were too few participants in the placebo group with
hypokalemia to analyze events.
|
|
|
Discussion |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
The 7.2% of participants in the active treatment group who experienced hypokalemia had a similar risk of CVD, CHD, and stroke as those randomized to placebo. Within the active treatment group, the risk of cardiovascular events was
50% lower among
those who had normal serum potassium levels compared with those who
experienced hypokalemia. These associations remained unchanged and
significant after adjustment for or stratification on a broad range of
cardiovascular risk factors and study drug doses and
were not explained by differences in blood pressure control. No
conclusions can be drawn on the effects of hypokalemia on all-cause
mortality because the number of deaths in the low-potassium group was
small and the hazard ratios had wide confidence intervals. According to the SHEP protocol, patients received potassium supplements after 2 determinations of serum potassium <3.5 mmol/L. Several factors can account for the finding that, despite this intervention, 7.2% of the patients in the active treatment group had hypokalemia at the first annual follow-up visit: potassium supplements may have been ineffective or insufficient, patients may have not been compliant with potassium supplement therapy, or in some participants, this may have been the first detection of hypokalemia.
Studies of the safety of commonly used medicines are subject to confounding by indication for the specific therapy.10 Although in SHEP the treatment was randomly assigned, the dose of chlorthalidone prescribed was dependent on a person’s blood pressure response. It is possible that participants who need higher doses of chlorthalidone to control hypertension have an increased cardiovascular risk. However, adjustment for or stratification on study drug dose did not modify the association of hypokalemia with the risk of cardiovascular events. Furthermore, hypokalemia was not associated with an increased cardiovascular risk profile at baseline or poorer blood pressure control during follow-up.
The 610 participants excluded from the analyses because of missing potassium measurements had a worse cardiovascular risk profile and were more likely to be randomized to placebo compared with those included in the analyses. Consequently, the present analyses included relatively healthier placebo participants. Confounding, if any, could only have diluted the association of hypokalemia with cardiovascular disease. Additionally, the data were analyzed according to the intention-to-treat principle by using the participant’s original treatment assignment. Again, this conservative analytical approach might have diluted the findings.
Hypokalemia induced by high-dose diuretics has been associated with ventricular arrhythmias and cardiac arrest.11 12 13 This effect might explain the lack of benefit of blood pressure lowering on the risk of coronary heart disease found in earlier studies.1 6 In SHEP, low-dose thiazide treatment without a potassium-sparing drug was not associated with a reduced risk of sudden cardiac death.3 However, an ancillary study of 186 SHEP participants showed that chlorthalidone did not increase the occurrence of ventricular premature complexes, although potassium levels were lower among participants randomized to diuretic treatment compared with those receiving placebo.14 Because of there were few sudden cardiac deaths among those with hypokalemia, we could not analyze this outcome.
Studies on diet support the view that potassium levels may affect the risk of stroke and cardiovascular events. The association between potassium and stroke has been investigated in several epidemiological15 16 17 and animal studies,18 19 20 21 22 showing that high intake of potassium is protective for the risk of stroke. High-potassium intake has been associated with modest reductions in blood pressure,23 24 especially among hypertensive persons,25 but the effect is variable26 27 and does not fully explain the strong inverse association with stroke.16 We did not find a higher blood pressure in participants with hypokalemia, and their higher risk of stroke could not be explained by differences in blood pressure.
A mechanism that may explain the association between low potassium and cardiovascular events includes free radical formation from vascular endothelial cells.28 Physiological increases in potassium concentration inhibit the rate of superoxide anion formation by cell lines derived from the endothelium. Physiological increases in potassium concentration also reduce the proliferation of cultured vascular smooth muscle cell proliferation29 and inhibit platelet aggregation and arterial thrombosis.30 31 Raising extracellular potassium concentration by 1 mmol/L increments from 3 to 7 mmol/L caused a highly significant decrease of free radical formation, smooth muscle proliferation, and thrombus formation, with the greatest decrement between 3 and 4 mmol/L.28 29 30 31 The clinical relevance of these animal or in vitro studies, however, remains to be established.
In conclusion, 7.2% of the participants in SHEP who received active
treatment were hypokalemic at the first annual visit and did not
experience the beneficial effect of blood pressure lowering on the risk
of cardiovascular events as seen among those with
potassium 
3.5 mmol/L. The current guidelines of the Joint
National Committee (JNC) on Prevention, Detection, Evaluation, and
Treatment of high blood pressure recommend diuretics as the
preferred agents in older persons with isolated systolic
hypertension.32 The present findings support the
importance of monitoring serum potassium during low-dose
diuretic treatment to identify the few patients who may not
benefit from diuretic treatment.
|
Acknowledgments |
|---|
The Systolic Hypertension in the Elderly Program (SHEP) was supported by grants from the National Heart, Lung, and Blood Institute (R03 HL-5995-01A1) and the National Institute on Aging. Drugs were supplied by the Lemmon Co, Sellersville, Penn; Wyeth Laboratories/Ayerst Laboratories and AH Robins Co, Richmond, Va; and Stuart Pharmaceuticals, Wilmington, Del.
Received September 7, 1999; first decision September 24, 1999; accepted December 13, 1999.
|
References |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
1. Siscovick DS, Raghunathan TE, Psaty BM, Koepsell TD, Wicklund KG, Lin X, Cobb L, Rautaharju PM, Copass MK, Wagner EH. Diuretic therapy for hypertension and the risk of primary cardiac arrest. N Engl J Med. 1994;330:1852–1857.
2.
Multiple Risk Factor Intervention Trial Research
Group. Multiple risk factor intervention trial: risk factor changes and
mortality results. JAMA. 1982;248:1465–1477.
3.
SHEP Cooperative Research Group. Prevention of stroke
by antihypertensive drug treatment in older persons with isolated
systolic hypertension: final results of the Systolic
Hypertension in the Elderly Program (SHEP). JAMA. 1991;265:3255–3264.
4. MRC Working Party. Medical Research Council trial of treatment of hypertension in older adults: principal results. BMJ. 1992;304:405–412.
5. Dahlof B, Lindholm LH, Hansson L, Schersten B, Ekbom T, Wester PO. Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP-Hypertension). Lancet. 1991;338:1281–1285.[Medline] [Order article via Infotrieve]
6.
Psaty BM, Smith NL, Siscovick DS, Koepsell TD, Weiss
NS, Heckbert SR, Lemaitre RN, Wagner EH, Furberg CD. Health outcomes
associated with antihypertensive therapies used as first-line agents: a
systematic review and meta-analysis. JAMA. 1997;277:739–745.
7.
Savage PJ, Pressel SL, Curb JD, Schron EB, Applegate
WB, Black HR, Cohen J, Davis BR, Frost P, Smith W, Gonzalez N, Guthrie
GP, Oberman A, Rutan G, Probstfield JL, Stamler J. Influence
of long-term, low-dose, diuretic-based, antihypertensive
therapy on glucose, lipid, uric acid, and potassium levels in older men
and women with isolated systolic hypertension: The
Systolic Hypertension in the Elderly Program. SHEP Cooperative
Research Group. Arch Intern Med. 1998;158:741–751.
8. Statistical Package for the Social Sciences Advanced Statistics Reference Guide. Release 7.5 ed. Chicago, Ill: SPSS Inc; 1997.
9. Cox DR. Regression models and life tables. J R Stat Soc. 1972;34b:187–220.
10. Psaty BM, Koepsell TD, Lin D, Weiss NS, Siscovick DS, Rosendaal FR, Pahor M, Furberg CD. Assessment and control for confounding by indication in observational studies. J Am Geriatr Soc. 1999;47:749–754.[Medline] [Order article via Infotrieve]
11. Grobbee DE, Hoes AW. Non-potassium-sparing diuretics and risk of sudden cardiac death. J Hypertens. 1995;13(pt 2):1539–1545.
12. Hoes AW, Grobbee DE, Lubsen J. Sudden cardiac death in patients with hypertension: an association with diuretics and beta-blockers? Drug Saf. 1997;16:233–241.[Medline] [Order article via Infotrieve]
13. Cohen JD, Neaton JD, Prineas RJ, Daniels KA. Diuretics, serum potassium and ventricular arrhythmias in the Multiple Risk Factor Intervention Trial. Am J Cardiol. 1987;60:548–554.[Medline] [Order article via Infotrieve]
14. Kostis JB, Lacy CR, Hall WD, Wilson AC, Borhani NO, Krieger SD, Cosgrove NM. The effect of chlorthalidone on ventricular ectopic activity in patients with isolated systolic hypertension: the SHEP Study Group. Am J Cardiol.. 1994;74:464–467.[Medline] [Order article via Infotrieve]
15.
Gillman MW, Cupples LA, Gagnon D, Posner BM, Ellison
RC, Castelli WP, Wolf PA. Protective effect of fruits and vegetables on
development of stroke in men. JAMA. 1995;273:1113–1117.
16.
Ascherio A, Rimm EB, Hernan MA, Giovannucci EL, Kawachi
I, Stampfer MJ, Willett WC. Intake of potassium, magnesium, calcium,
and fiber and risk of stroke among US men. Circulation. 1998;98:1198–1204.
17. Khaw KT, Barrett-Connor E. Dietary potassium and stroke-associated mortality: a 12-year prospective population study. N Engl J Med. 1987;316:235–240.[Abstract]
18. Ishimitsu T, Tobian L, Sugimoto K, Everson T. High potassium diets reduce vascular and plasma lipid peroxides in stroke-prone spontaneously hypertensive rats. Clin Exp Hypertens. 1996;18:659–673.
19. Ishimitsu T, Tobian L, Sugimoto K, Lange JM. High potassium diets reduce macrophage adherence to the vascular wall in stroke-prone spontaneously hypertensive rats. J Vasc Res. 1995;32:406–412.[Medline] [Order article via Infotrieve]
20. Sugimoto K, Tobian L, Ishimitsu T, Lange JM. High potassium diets greatly increase growth-inhibiting agents in aortas of hypertensive rats. Hypertension. 1992;19(pt 2):749–752.
21. Tobian L, Lange J, Ulm K, Wold L, Iwai J. Potassium reduces cerebral hemorrhage and death rate in hypertensive rats, even when blood pressure is not lowered. Hypertension. 1985;7(pt 2):I110–I114.
22. Tobian L, Lange JM, Johnson MA, MacNeill DA, Wilke TJ, Ulm KM, Wold LJ. High-K diets reduce brain haemorrhage and infarcts, death rate and mesenteric arteriolar hypertrophy in stroke-prone spontaneously hypertensive rats. J Hypertens. 1986;4:S205–S207.
23.
Sacks FM, Willett WC, Smith A, Brown LE, Rosner B,
Moore TJ. Effect on blood pressure of potassium, calcium, and magnesium
in women with low habitual intake. Hypertension. 1998;31:131–138.
24.
Whelton PK, He J, Cutler JA, Brancati FL, Appel LJ,
Follmann D, Klag MJ. Effects of oral potassium on blood pressure:
meta-analysis of randomized controlled clinical trials.
JAMA. 1997;277:1624–1632.
25. Cappuccio FP, MacGregor GA. Does potassium supplementation lower blood pressure? A meta-analysis of published trials. J Hypertens. 1991;9:465–473.[Medline] [Order article via Infotrieve]
26. MacGregor GA, Smith SJ, Markandu ND, Banks RA, Sagnella GA. Moderate potassium supplementation in essential hypertension. Lancet. 1982;2:567–570.[Medline] [Order article via Infotrieve]
27. Richards AM, Nicholls MG, Espiner EA, Ikram H, Maslowski AH, Hamilton EJ, Wells JE. Blood-pressure response to moderate sodium restriction and to potassium supplementation in mild essential hypertension. Lancet. 1984;1:757–761.[Medline] [Order article via Infotrieve]
28.
McCabe RD, Bakarich MA, Srivastava K, Young DB.
Potassium inhibits free radical formation. Hypertension. 1994;24:77–82.
29. McCabe RD, Young DB. Potassium inhibits cultured vascular smooth muscle cell proliferation. Am J Hypertens. 1994;7(pt 1):346–350.
30.
Lin H, Young DB. Interaction between plasma potassium
and epinephrine in coronary thrombosis in dogs.
Circulation. 1994;89:331–338.
31. Young DB, Lin H, McCabe RD. Potassium’s cardiovascular protective mechanisms. Am J Physiol. 1995;268(pt 2):R825–R837.
32.
Joint National Committee. The sixth report of the Joint
National Committee on Prevention, Detection, Evaluation, and Treatment
of high blood pressure. Arch Intern Med. 1997;157:2413–2446.
This article has been cited by other articles:
 |
|
 |
|
  On behalf of the Canadian Hypertension Education P 2009 Canadian Hypertension Education Program recommendations: An annual update Can Fam Physician, July 1, 2009; 55(7): 697 - 700. [Full Text] [PDF]
|
|
|
|
 |
|
 O. E. Osadchii, B. H. Bentzen, and S. P. Olesen Chamber-specific effects of hypokalaemia on ventricular arrhythmogenicity in isolated, perfused guinea-pig heart Exp Physiol, April 1, 2009; 94(4): 434 - 446. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Parra, R. Rosenstein, M. H. Strauss, J. Weinstein, G. E. Newton, B. R. Davis, P. K. Whelton, the ALLHAT Collaborative Research Group, K. A. Jamerson, and M. A. Weber Benazepril plus Amlodipine or Hydrochlorothiazide for Hypertension N. Engl. J. Med., March 12, 2009; 360(11): 1147 - 1150. [Full Text] [PDF]
|
|
|
|
 |
|
 R. Agarwal Hypertension, Hypokalemia, and Thiazide-Induced Diabetes: A 3-Way Connection Hypertension, December 1, 2008; 52(6): 1012 - 1013. [Full Text] [PDF]
|
|
|
|
|
|
B. L. Carter, P. T. Einhorn, M. Brands, J. He, J. A. Cutler, P. K. Whelton, G. L. Bakris, F. L. Brancati, W. C. Cushman, S. Oparil, et al. Thiazide-Induced Dysglycemia: Call for Research From a Working Group From the National Heart, Lung, and Blood Institute Hypertension, July 1, 2008; 52(1): 30 - 36. [Full Text] [PDF]
|
|
|
|
 |
|
 A. Ahmed, F. Zannad, T. E. Love, J. Tallaj, M. Gheorghiade, O. J. Ekundayo, and B. Pitt A propensity-matched study of the association of low serum potassium levels and mortality in chronic heart failure Eur. Heart J., June 1, 2007; 28(11): 1334 - 1343. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. T. Sawicki and N. McGauran Have ALLHAT, ANBP2, ASCOT-BPLA, and So Forth Improved Our Knowledge About Better Hypertension Care? Hypertension, July 1, 2006; 48(1): 1 - 7. [Full Text] [PDF]
|
|
|
|
 |
|
 P. Chen, J. P. Guzman, P. K. K. Leong, L. E. Yang, A. Perianayagam, E. Babilonia, J. S. Ho, J. H. Youn, W. H. Wang, and A. A. McDonough Modest dietary K+ restriction provokes insulin resistance of cellular K+ uptake and phosphorylation of renal outer medulla K+ channel without fall in plasma K+ concentration Am J Physiol Cell Physiol, May 1, 2006; 290(5): C1355 - C1363. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Stults and R. E. Jones Management of Hypertension in Diabetes Diabetes Spectr, January 1, 2006; 19(1): 25 - 31. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Q. Wang, A. A. Domenighetti, T. Pedrazzini, and M. Burnier Potassium Supplementation Reduces Cardiac and Renal Hypertrophy Independent of Blood Pressure in DOCA/Salt Mice Hypertension, September 1, 2005; 46(3): 547 - 554. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Morganti Should a Diuretic Always Be the First Choice in Patients with Essential Hypertension? The Case for No J. Am. Soc. Nephrol., March 1, 2005; 16(3_suppl_1): S70 - S73. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Mancia and G. Grassi Joint National Committee VII and European Society of Hypertension/European Society of Cardiology Guidelines for Evaluating and Treating Hypertension: A Two-Way Road? J. Am. Soc. Nephrol., March 1, 2005; 16(3_suppl_1): S74 - S77. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. Hoch, A. D. Heymann, I. Kurman, L. J. Valinsky, G. Chodick, and V. Shalev Reply to Atreja et al. J. Am. Med. Inform. Assoc., September 1, 2004; 11(5): 435 - 435. [Full Text] [PDF]
|
|
|
|
 |
|
 M. A. Fischer and J. Avorn Economic Implications of Evidence-Based Prescribing for Hypertension: Can Better Care Cost Less? JAMA, April 21, 2004; 291(15): 1850 - 1856. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Moser ALLHAT Debate: Diuretics Are Not Preferred, First-Line Initial Therapy for Hypertension--Reply Arch Intern Med, March 8, 2004; 164(5): 571 - 572. [Full Text] [PDF]
|
|
|
|
|
|
M. C. Houston ALLHAT Debate: Diuretics Are Not Preferred, First-Line Initial Therapy for Hypertension Arch Intern Med, March 8, 2004; 164(5): 570 - 571. [Full Text] [PDF]
|
|
|
|
 |
|
 J. E. Macdonald and A. D. Struthers What is the optimal serum potassium level in cardiovascular patients? J. Am. Coll. Cardiol., January 21, 2004; 43(2): 155 - 161. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Miltiadous, D. P. Mikhailidis, and M. Elisaf Acid-Base and Electrolyte Abnormalities Observed in Patients Receiving Cardiovascular Drugs Journal of Cardiovascular Pharmacology and Therapeutics, December 1, 2003; 8(4): 267 - 276. [Abstract] [PDF]
|
|
|
|
|
|
A. V. Chobanian, G. L. Bakris, H. R. Black, W. C. Cushman, L. A. Green, J. L. Izzo Jr, D. W. Jones, B. J. Materson, S. Oparil, J. T. Wright Jr, et al. Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure Hypertension, December 1, 2003; 42(6): 1206 - 1252. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. N Basile Systolic blood pressure BMJ, October 26, 2002; 325(7370): 917 - 918. [Full Text] [PDF]
|
|
|
|
 |
|
 N. R.C. Campbell, D. Drouin, and R. D. Feldman The 2001 Canadian hypertension recommendations: take-home messages Can. Med. Assoc. J., September 1, 2002; 167(6): 661 - 668. [Full Text] [PDF]
|
|
|
|
 |
|
 D. M. Green, A. H. Ropper, R. A. Kronmal, B. M. Psaty, and G. L. Burke Serum potassium level and dietary potassium intake as risk factors for stroke Neurology, August 13, 2002; 59(3): 314 - 320. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Sato, Y. Hasegawa, J. Nakae, K. Nanao, I. Takahashi, T. Tajima, N. Shinohara, and K. Fujieda Hydrochlorothiazide Effectively Reduces Urinary Calcium Excretion in Two Japanese Patients with Gain-of-Function Mutations of the Calcium-Sensing Receptor Gene J. Clin. Endocrinol. Metab., July 1, 2002; 87(7): 3068 - 3073. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. A. McDonough, C. B. Thompson, and J. H. Youn Skeletal muscle regulates extracellular potassium Am J Physiol Renal Physiol, June 1, 2002; 282(6): F967 - F974. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. H. Laragh and J. E. Sealey K+ Depletion and the Progression of Hypertensive Disease or Heart Failure : The Pathogenic Role of Diuretic-Induced Aldosterone Secretion Hypertension, February 1, 2001; 37(2): 806 - 810. [Full Text] [PDF]
|
|
|
|
 |
|
 Diuretics, Hypokalemia, and Cardiovascular Risk Journal Watch Cardiology, August 4, 2000; 2000(804): 6 - 6. [Full Text]
|
|
|
|
|
|
R. W. Schrier Diuretic Treatment of Systolic Hypertension in the Elderly Hypertension, May 1, 2000; 35(5): 1031 - 1031. [Full Text] [PDF]
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||